Please wait while the formulary information is being retrieved.
TAFINLAR (DABRAFENIB MESYLATE)
- Anaplastic thyroid carcinoma with BRAF v600E mutation
- Malignant melanoma with BRAF v600E mutation
- Malignant melanoma with BRAF v600K mutation
- Non-small cell lung cancer with BRAF v600E mutation
50 mg capsule
- 2 capsules (100 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
75 mg capsule
- 2 capsules (150 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
Anaplastic thyroid carcinoma with BRAF v600E mutation
- 1 capsule (50 mg) by oral route every 12 hours at least 1 hour before or 2 hours after meals
- 1 capsule (75 mg) by oral route every 12 hours at least 1 hour before or 2 hours after meals
- 2 capsules (100 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
- 2 capsules (150 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
Malignant melanoma with BRAF v600E mutation
- 1 capsule (50 mg) by oral route every 12 hours at least 1 hour before or 2 hours after meals
- 1 capsule (75 mg) by oral route every 12 hours at least 1 hour before or 2 hours after meals
- 2 capsules (100 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
- 2 capsules (150 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
Malignant melanoma with BRAF v600K mutation
- 1 capsule (50 mg) by oral route every 12 hours at least 1 hour before or 2 hours after meals
- 1 capsule (75 mg) by oral route every 12 hours at least 1 hour before or 2 hours after meals
- 2 capsules (100 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
- 2 capsules (150 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
Non-small cell lung cancer with BRAF v600E mutation
- 1 capsule (50 mg) by oral route every 12 hours at least 1 hour before or 2 hours after meals
- 1 capsule (75 mg) by oral route every 12 hours at least 1 hour before or 2 hours after meals
- 2 capsules (100 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
- 2 capsules (150 mg) by oral route every 12 hours at least 1 hourbefore or 2 hours after meals
- None
Contraindicated
- Altavera (28)
- Alyacen 1/35 (28)
- Alyacen 7/7/7 (28)
- Amethia
- Amethia Lo
- Amethyst
- Apri
- Aranelle (28)
- Aubra
- Aviane
- axitinib
- Azurette (28)
- B cplx-C-St.Johnwrt-K.&S.ginsg
- Balziva (28)
- bedaquiline
- Belladonna-phenobarbital
- Beyaz
- Bosulif
- bosutinib
- Brevicon (28)
- Briellyn
- calcium-mag-B complex-D3-hrb61
- Camila
- Camrese
- Camrese Lo
- carbamazepine
- Carbatrol
- Caziant (28)
- Cerebyx
- Chateal
- Cold & Flu Fighter
- Cryselle (28)
- Cyclafem 1/35 (28)
- Cyclafem 7/7/7 (28)
- Cyclessa (28)
- Dasetta 1/35 (28)
- Dasetta 7/7/7 (28)
- Daysee
- Depo-provera
- Depo-subq Provera 104
- desog-e.estradiol/e.estradiol
- Desogen
- desogestrel-ethinyl estradiol
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Diflucan
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- drospirenone-e.estradiol-lm.FA
- drospirenone-ethinyl estradiol
- Elinest
- Emoquette
- Enpresse
- Enskyce
- enzalutamide
- Epitol
- Equetro
- Errin
- Estarylla
- estradiol valerate-dienogest
- Estrostep Fe-28
- ethynodiol diac-eth estradiol
- etonogestrel
- etonogestrel-ethinyl estradiol
- Falmina (28)
- Fatigue Relief Complex
- Femcon Fe
- fluconazole
- fluconazole in dextrose(iso-o)
- fluconazole in NaCl (iso-osm)
- fosphenytoin
- gemfibrozil
- Generess Fe
- Gianvi (28)
- Gildagia
- Gildess
- Gildess Fe
- guanfacine
- Heather
- Inlyta
- Introvale
- Intuniv Er
- isoniazid-rifamp-pyrazinamide
- Jencycla
- Jolessa
- Jolivette
- Junel 1.5/30 (21)
- Junel 1/20 (21)
- Junel Fe 1.5/30 (28)
- Junel Fe 1/20 (28)
- Kariva (28)
- Kelnor 1/35 (28)
- Kurvelo
- L norgest&E estradiol-E estrad
- Larin 1/20 (21)
- Larin Fe
- Leena 28
- Lessina
- Levonest (28)
- levonorg-eth estrad triphasic
- levonorgestrel
- levonorgestrel-ethinyl estrad
- Levora 0.15/30 (28)
- Levora-28
- Lo Loestrin Fe
- Loestrin 1.5/30 (21)
- Loestrin 1/20 (21)
- Loestrin Fe 1.5/30 (28)
- Loestrin Fe 1/20 (28)
- Lomedia 24 Fe
- Lopid
- Loryna (28)
- Loseasonique
- Low-ogestrel (28)
- Luminal
- Lutera (28)
- Lyza
- Marlissa
- medroxyprogesterone
- Microgestin 1.5/30 (21)
- Microgestin 1/20 (21)
- Microgestin Fe 1.5/30 (28)
- Microgestin Fe 1/20 (28)
- Minastrin 24 Fe
- Mircette (28)
- Mirena
- Modicon (28)
- Mono-linyah
- Mononessa (28)
- My Way
- Mycobutin
- Mysoline
- Myzilra
- Natazia
- Necon 0.5/35 (28)
- Necon 1/35 (28)
- Necon 1/50 (28)
- Necon 10/11 (28)
- Necon 7/7/7 (28)
- Nexplanon
- Next Choice One Dose
- Nor-qd
- Nora-be
- norelgestrom-ethinyl estradiol
- noreth-ethinyl estradiol-iron
- norethin-e.estradiol triphasic
- norethin-eth estrad biphasic
- norethindrone (contraceptive)
- norethindrone ac-eth estradiol
- norethindrone-e.estradiol-iron
- norethindrone-ethin estradiol
- norethindrone-mestranol
- norgestimate-ethinyl estradiol
- norgestrel-ethinyl estradiol
- Norinyl 1+35 (28)
- Norinyl 1+50 (28)
- Nortrel 0.5/35 (28)
- Nortrel 1/35 (21)
- Nortrel 1/35 (28)
- Nortrel 7/7/7 (28)
- Nuvaring
- Ocella
- Ogestrel (28)
- Olysio
- Orsythia
- Ortho Evra
- Ortho Micronor
- Ortho Tri-cyclen (28)
- Ortho Tri-cyclen Lo (28)
- Ortho-cept (28)
- Ortho-cyclen (28)
- Ortho-novum 1/35 (28)
- Ortho-novum 7/7/7 (28)
- Ovcon-35 (28)
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Philith
- Pimtrea (28)
- Pirmella
- Plan B One-step
- Portia
- Previfem
- primidone
- Quartette
- Quasense
- Reclipsen (28)
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- Safyral
- Seasonique
- simeprevir
- Sirturo
- Sprintec (28)
- Sronyx
- St. John's wort
- Syeda
- Tegretol
- Tegretol Xr
- Tenex
- Tilia Fe
- Tri-estarylla
- Tri-legest Fe
- Tri-linyah
- Tri-norinyl (28)
- Tri-previfem (28)
- Tri-sprintec (28)
- Trinessa (28)
- Trivora (28)
- Velivet Triphasic Regimen (28)
- Vestura (28)
- Viorele (28)
- vit C-St. John wort-elder-hb30
- Vyfemla (28)
- Wera (28)
- Women's Complex
- Wymzya Fe
- Xtandi
- Yasmin (28)
- Yaz 28
- Zarah
- Zenchent (28)
- Zenchent Fe
- Zeosa
- Zovia 1/35E (28)
- Zovia 1/50E (28)
Severe
Moderate
- ospemifene
- Osphena
- Hemolytic anemia from PK and g6PD deficiencies
- Lactating mother
- Progression of malignancy associated with RAS mutation
Contraindicated
- Basal cell carcinoma of skin
- Chronic heart failure
- Congenital long QT syndrome
- Glucose-6-phosphate dehydrogenase deficiency anemia
- Hemorrhage
- High fever >101 degrees fahrenheit
- Iritis
- Keratoacanthoma
- Pregnancy
- Squamous cell carcinoma
- Uveitis
Severe
Moderate
- Diabetes mellitus
- Severe hepatic disease
TAFINLAR (DABRAFENIB MESYLATE)
- Anaplastic thyroid carcinoma with BRAF v600E mutation
- Malignant melanoma with BRAF v600E mutation
- Malignant melanoma with BRAF v600K mutation
- Non-small cell lung cancer with BRAF v600E mutation
- None
- Alopecia
- Arthralgias
- Cutaneous papilloma
- Fever
- Headache disorder
- Hyperkeratosis
- Palmar-plantar erythrodysesthesia
More Frequent
Severe
Less Severe
- Cardiomyopathy
- Gastrointestinal hemorrhage
- Hemorrhage
- Hypotension
- Interstitial nephritis
- Keratoacanthoma
- Left ventricular failure
- Pancreatitis
- Panniculitis
- Renal failure
- Second primary melanoma
- Skin rash
- Squamous cell carcinoma
- Thromboembolic disorder
- Uveitis
- Back pain
- Basal cell carcinoma of skin
- Chills
- Cough
- Dehydration
- Hyperglycemia
- Myalgias
- Pharyngitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Bullous dermatitis
- Colitis
- Gastrointestinal perforation
- Intracranial bleeding
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Dabrafenib
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Dabrafenib
- Severity Level:
D
- Additional Notes: Insuff human data; teratogenic and embryotoxic in rats at 3 times mrhd
Contraindicated
Dabrafenib
Insuff data avail; based on mech of action, potential for infant adv effects
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff data avail; based on mech of action, potential for infant adv effects |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Dabrafenib
General-Increased incidence of peripheral edema (26% vs. 12%) and anorexia (21% vs. 9%) as compared to younger patients in the metastatic melanoma studies.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Anaplastic thyroid carcinoma with BRAF v600E mutation | |
| C73 | Malignant neoplasm of thyroid gland |
| Malignant melanoma with BRAF v600E mutation | |
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
| Malignant melanoma with BRAF v600K mutation | |
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
| Non-small cell lung cancer with BRAF v600E mutation | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| 0-9 | A-Z |
|---|---|
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| C43 | Malignant melanoma of skin |
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
| C43.9 | Malignant melanoma of skin, unspecified |
| C73 | Malignant neoplasm of thyroid gland |
Formulary Reference Tool